Sascha Tillmanns

Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation

G. Zimmermann, Rainer Baumgartner, Hanno Leuchte et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2009 · 71 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano et al. · Blood · 2019 · 26 citations

Life Sciences, Immunology, Oncology +13

Interim Results From a Phase Ib/IIa Clinical Trial with the Soluble Fc-Gamma IIb Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia

Tatyana Semenovna Konstaninova, Andrzej Hellmann, Sławomira Kyrcz‐Krzemień et al. · Blood · 2012 · 19 citations

Life Sciences, Hematology, Immunology +8

Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo

Beatrice Trammer, Annette Amann, Eleonore Haltner‐Ukomadu et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2008 · 14 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Grzegorz S. Nowakowski, Thomas D. Rodgers, Dario Marino et al. · Journal of Clinical Oncology · 2020 · 14 citations

Medicine, Oncology, Pharmacotherapy +14